Shots:

• X-Chem to receive an up front and is eligible to receive research- development and regulatory milestone along with royalties on sales of therapies resulting from the collaboration
• Genentech will lead further development and commercialization of any potential new therapies and retain exclusive rights to compounds derived from the collaboration. Additionally- Genentech get an exclusive license to an existing preclinical- small molecule program previously identified by X-Chem using its DEL platform
• X-Chem will leverage its DEL platform to identify novel leads against multiple oncology targets of interest to Genentech and may also conduct hit-to-lead optimization for the programs

 ­ Ref: Businesswire | Image: Business Wire